Specificity of action remains important; for example, the recent observation that PDE4D inhibition exerts anti-oncogenic action in liver cancer would be unlikely to apply to fibrolamellar hepatocellular carcinoma (179). Here, PDE4D is linked to fibrolamellar hepatocellular carcinoma.